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Abstract: (1) Background: Circulating tumor cell (CTC) clusters are emerging as clinically significant
harbingers of metastases in solid organ cancers. Prior to engaging these CTC clusters in animal
models of metastases, it is imperative for technology to identify them with high sensitivity. These
clusters often present heterogeneous surface markers and current methods for isolation of clusters
may fall short. (2) Methods: We applied an inertial microfluidic Labyrinth device for high-throughput,
biomarker-independent, size-based isolation of CTCs/CTC clusters from patients with metastatic
non-small-cell lung cancer (NSCLC). (3) Results: Using Labyrinth, CTCs (PanCK+/DAPI+/CD45−)
were isolated from patients (n = 25). Heterogeneous CTC populations, including CTCs expressing
epithelial (EpCAM), mesenchymal (Vimentin) or both markers were detected. CTCs were isolated
from 100% of patients (417± 1023 CTCs/mL). EpCAM−CTCs were significantly greater than EpCAM+
CTCs. Cell clusters of ≥2 CTCs were observed in 96% of patients—of which, 75% were EpCAM−.
CTCs revealed identical genetic aberrations as the primary tumor for RET, ROS1, and ALK genes
using fluorescence in situ hybridization (FISH) analysis. (4) Conclusions: The Labyrinth device
recovered heterogeneous CTCs in 100% and CTC clusters in 96% of patients with metastatic NSCLC.
The majority of recovered CTCs/clusters were EpCAM−, suggesting that these would have been
missed using traditional antibody-based capture methods.
Cancers 2020, 12, 127; doi:10.3390/cancers12010127 www.mdpi.com/journal/cancers
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1. Introduction
Cancer metastasis is the cause of cancer death in the vast majority of patients with solid organ
cancers, including lung cancer [1]. Circulating tumor cells (CTCs) represent a heterogeneous population
of malignant cells that disseminate from tumors into the bloodstream, as single cells or tumor cell
clusters, enabling their transportation to distant sites and the seeding of metastatic tumors [2]. Despite
decades of research, therapies to reduce and prevent metastases have mostly been elusive. CTCs have
been shown to correlate with incidence of metastasis after initial surgery and the numbers of CTCs
correlate with progression-free and overall survival in many cancers, including lung cancer [3–5].
CTC clusters are defined as groups of two or more aggregated CTCs, often consists of other
non-tumor cells including endothelial cells, erythrocytes, stromal cells, leukocytes, platelets, and
cancer associated fibroblasts found in the blood of patients with solid tumors [6]. This cocktail of cells
provides a local microenvironment for protection from death in the circulation by minimizing shear
stress, immune system attack and through facilitating colonization [7]. Although CTC clusters are
even rarer than single CTCs (about 3% of all CTC) [8], they have been observed in various cancers
including lung cancer [9]. More recently technological advances have allowed researchers to capture
CTC clusters. Several groups are studying these clusters as potential surrogates for tumor biology
and aggressiveness. We have previously demonstrated the presence of CTC clusters in patients with
early-stage lung cancer [4]. We have chosen here to focus our studies on the detection of these CTC
clusters in metastatic NSCLC.
Lung cancer is among the most prevalent forms of cancer and has one of the highest mortality
rates, with a 5 year survival rate of only 19% [10,11]. About 85% of lung cancers are classified as
non-small-cell lung cancer (NSCLC) [12]. Less than 30% of patients with NSCLC present with earlier
stages, allowing curative surgical resection [11]. The majority of patients present with locally advanced
or metastatic cancer. Despite improvements in targeted and immunotherapy, the overall survival is
dismal with less than 25% of all NSCLC patients living 5 years or longer. There are several unique
characteristics that contribute to the aggressiveness of NSCLC including late detection, high degree of
tumor heterogeneity and resistance to available therapies. There is an urgent, unmet need to identify
ways to improve earlier diagnosis/recurrence, capture tumor heterogeneity and understand why certain
lung cancers metastasize to specific organs such as the brain. Downstream molecular studies using
CTC clusters and performing in vivo experiments may give the answers to these questions. These
CTC clusters are characterized by the heterogeneity of surface markers just as individual CTCs. It is
therefore imperative to develop a platform that could enable high fidelity capture of these CTC clusters.
The detection of CTC clusters is even more challenging due to the rarity among other CTCs,
and possible dissociation of clusters during the blood sample processing [6]. Therefore, high-throughput
capability of isolation based on shape, size, composition, and label-free with minimum manipulation
would be an efficient platform to isolate CTC clusters [6].
CTC enrichment technologies utilize either biological (label-dependent or immunoaffinity-based)
or physical (label-independent or size-based) properties of cells [2,13–19]. Currently, available CTC
technologies more often depend on surface markers, such as EpCAM, to identify these cells, potentially
missing a large population that may be more “stem-like” in nature [20]. On the other hand, label-free
technologies, depending on size, density, and dielectrophoresis properties, isolate heterogeneous
population of CTCs. There are other label-free technologies available for CTC detection, for instance,
EPISPOT, which discriminates between viable and apoptotic CTCs using protein secretion [21],
FISH-based assays [22,23], and metabolic approaches that measure the fluctuations in pH or lactate
concentration in CTCs [24]. Label-free technologies are often limited by the throughput. Hence,
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a high-throughput microfluidic-based biomarker-independent CTC isolation technology can address
the current challenges [25].
CTC clusters were observed form patient blood samples using different technologies including
density-based cell separation apparatus (AccuCyte) (presence of clusters) [26], Epic (5.8 CTC clusters/mL
from metastatic NSCLC patient samples) [27], Vortex Chip (presence of clusters) [28], lithographic
microfilters (presence of clusters) [29], ScreenCell (presence of clusters) [30], Cluster Chip (30%–40% of
patients ranging from 0.1–0.5 clusters/mL) [31], and flexible micro spring array (FMSA) (30% of NSCLC
patient samples) [32]. A detailed review of CTC cluster capture platforms was performed by Rostami
et al [6]. Herein, we present a technological advance using a high-throughput, label-independent,
size-based inertial microfluidic separation device, Labyrinth, previously used to detect CTCs in breast
and pancreatic cancer patients [25]. Both inertial focusing and Dean flow were incorporated for
size-based separation, enabling the continuous focusing of all cells while separating CTCs from smaller
blood cells at the outlet [25]. However, the main disadvantage of size-based separation methods is the
loss of smaller CTCs, which may result in losing valuable information from the patient [33,34].
2. Results
2.1. Optimization of Labyrinth for Cell Recovery
The microfluidic Labyrinth device consists of a long curvature path (as shown in Figure 1A by
loading Labyrinth with red dye to delineate the device’s structure), an inlet through which the sample
is introduced and four outlet channels. Typically, most of the white blood cells (WBCs) are collected
through outlet 1, whereas CTCs from outlet #2 (Figure 1A).
The device was optimized and tested for inertial separation of cancer cells using human lung cancer
cell line, H1650. To demonstrate cell focusing in the device, the same concentration of pre-labeled cancer
cells with CellTracker Green and pre-labeled WBCs with DAPI (4′,6-diamidino-2-phenylindole) (each
1000 cells/mL) were spiked into phosphate-buffered saline (PBS) and separated using the Labyrinth.
Different flow rates ranging from 2300–2500 µL/min were tested for further optimization. Products
were collected after flow stabilization (1.5 min) and the percentage of CTC recovery and WBC depletion
were determined by cell counting. Using the H1650 cell line, 82% ± 5% of cancer cells were recovered
at a flow rate of 2500 µL/min (Figure 1B), while 78% ± 18% of WBCs were removed (Figure 1C).
To identify CTCs in patient samples, immunofluorescence (IF) staining was optimized with a panel
of antibodies (anti-human CD45 (cluster of differentiation 45), anti-human PanCK (pan-Cytokeratin),
anti-human EpCAM (Epithelial cell adhesion molecule), and anti-human Vimentin) using lung cancer
cell lines including H1975 and A549. We were able to show that both H1975 and A549 were positive
for PanCK and negative for CD45, whereas these cells expressed EpCAM and Vimentin differentially
as expected (Figure 1D).
2.2. Isolation of CTCs from NSCLC Patients
Peripheral blood samples were collected from 25 patients with metastatic, stage IV NSCLC
(Table S1). Among these 25 patients, there were patients with EGFR mutations (n = 15), ROS1
rearrangements (n = 6), and ALK fusion (n = 4). These patient samples were processed through the
Labyrinth (as described in the Materials and Methods).
After CTC isolation, the product from outlet #2 was analyzed for CTCs. CTCs were detected
by IF staining as described in the Materials and Methods. Cells with the PanCK+/CD45−/DAPI+
phenotype were identified and enumerated as CTCs. Figure 2A shows IF staining of an isolated single
CTC stained positive for PanCK (red) and negative for CD45 (green) to distinguish CTCs from WBCs.
Figure 2B,C illustrate confocal images of isolated CTCs in clusters of two (Figure 2B) and three cells
(Figure 2C). We determined that all 25 patients (100%) had detectable CTCs with an average of 417
CTC/mL (10.2–5068) (Figure 2D). In contrast, low numbers of CTC/mL (0–3) were observed in the
healthy controls (HCs, n = 3) (p = 0.0006) (Figure 2D and Figure S1) (Table S2).
Cancers 2020, 12, 127 4 of 17
Figure 1. Optimization of Labyrinth for cell recovery. (A) The Labyrinth was loaded with red dye to
show the device’s structure as well as the inlet and outlets. (B,C) Using the H1650 lung cancer cell
line, different flow rates ranging from 2300–2500 µL/min were tested for inertial separation of cancer
cells. Pre-labeled H1650 cell line and DAPI (4′,6-diamidino-2-phenylindole)-labeled white blood cells
(WBCs) (1000 cells) were spiked into PBS and processed through the Labyrinth. Using a flow rate
of 2500 µL/min, 82% ± 5% of H1650 cells were recovered from outlet #2 and 78% ± 18% of WBCs
were removed through outlet #1. (D) Immunofluorescence staining optimization. Anti-human CD45
(cluster of differentiation 45) (green), anti-human PanCK (pan-Cytokeratin) (red), anti-human EpCAM
(Epithelial cell adhesion molecule) (orange), and anti-human Vimentin (pink) antibodies were tested
with lung cancer cell lines, H1975 and A549.
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Figure 2. Isolation of circulating tumor cells (CTCs) from non-small-cell lung cancer (NSCLC) patients
(n = 25). (A) Fluorescent microscope image of a single CTC. Cells are stained with DAPI (blue), PanCK
(red) and CD45 (green). (B,C) Confocal microscopy images of some CTC clusters. (D) An individual
bar plot of the number of CTCs recovered from NSCLC patient samples at baseline, using Labyrinth.
The overall number of CTCs in NSCLC patient samples was 417 ± 1023 per mL, while healthy controls
had 1 ± 1.7 CTCs per mL.
2.3. Identification of Heterogeneous Subpopulations of CTCs Isolated Using Labyrinth
Isolated CTCs from a subset of NSCLC patients (n = 23) were further examined to determine the
percentage of cells that displayed epithelial and mesenchymal markers (Table S2). We used EpCAM
(for epithelial phenotype) and Vimentin (for mesenchymal phenotype), in addition to PanCK (tumor
marker), CD45 (leukocyte marker), and DAPI (nuclear marker). CTCs were defined as cells positive
for PanCK, and DAPI, but negative for CD45. We further categorized CTCs into subpopulations based
on expression of EpCAM, Vimentin, or double expression of EpCAM and Vimentin (Figure 3A).
Figure 3B,C demonstrate the percentage of CTCs expressing EpCAM (EpCAM+/− in dark/light
orange, respectively) and CTCs expressing Vimentin (Vimentin+/− in dark/light pink, respectively)
from each patient. Of 23 patients, 17 demonstrated higher numbers of EpCAM− CTCs than EpCAM+
CTCs and six demonstrated higher numbers of EpCAM+ CTCs than EpCAM− CTCs. Of the captured
CTCs among all patient samples (n = 23), 31% (96 CTCs/mL) were EpCAM+ CTCs, whereas 69%
(336 CTCs/mL) were EpCAM− CTCs (p = 0.01) (Figure 3B and Figure S2A), 45% (346 CTCs/mL) were
Vimentin+ CTCs and 55% (85 CTCs/mL) were Vimentin− CTCs (Figure 3C and Figure S2A).
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Figure 3. Identification of heterogeneous CTC subpopulations isolated from NSCLC patient samples
(n = 23). (A) Fluorescent microscope images of different subpopulations of CTCs (CTCs, EpCAM+
CTCs, Vimentin+ CTCs, and Double+ CTCs). Cells are stained with DAPI (blue), CD45 (green), PanCK
(red), EpCAM (orange), and Vimentin (pink). (B,C) The percentage of CTCs expressing both EpCAM
(B) and Vimentin (C) recovered from each NSCLC patient sample (n = 23). The EpCAM+/− CTCs
is shown in dark/light orange respectively and the Vimentin+/− CTCs is shown in dark/light pink
respectively. An average of 31% of the captured CTCs were EpCAM+ and 69% were EpCAM− CTCs.
An average of 45% of the captured CTCs were Vimenin+ and 55% were Vimentin− CTCs. The total
number of CTCs/mL across all patient samples is shown on the bottom of the graph.
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2.4. CTC Clusters Isolation by Using Labyrinth
To investigate the ability of Labyrinth to isolate CTC clusters, we analyzed the CTCs isolated from
the above cohort of patients for the presence of clusters (Figure 4A) (Tables S2 and S3). In addition to
single CTCs, a large number of CTCs were observed in cluster forms (2 to 8 CTCs/cluster). On average,
31 ± 26 CTCs/mL of the recovered CTCs were in the form of single CTCs, whereas 386 ± 1025 CTCs/mL
were in cluster forms (p = 0.001) (Figure 4B,C). The majority of patients (24/25) presented CTC clusters.
Of the 24 patients with CTC clusters, 23 had ≥2 clusters. The majority (n = 22) presented with at least
three CTC clusters. There were others with four clusters (n = 11), five clusters (n = 8), six clusters (n = 3),
seven clusters (n = 3) and eight clusters (n = 1) (Figure 4D). Significantly higher numbers of recovered
clusters from Labyrinth were EpCAM− (p = 0.005) (Figure S2B) and 41% of the recovered CTC clusters
displayed mesenchymal marker Vimentin (p = 0.007) (Figure 4E), suggestive of a preponderance of
an epithelial-to-mesenchymal transition (EMT) phenotype in CTC clusters [7]. Based on our results,
the group of patients who had a higher number of CTC clusters than single CTCs showed worse
progression-free survival (PFS) (25 vs. 51 months p = 0.05) (Figure 4F). However, the difference was
not statistically significant.
2.5. Genomic Analysis of Recovered CTCs Using Fluorescence In Situ Hybridization (FISH) Analysis
To investigate whether CTCs isolated by Labyrinth carry the genomic signature of the primary
tumor, we analyzed CTCs from selected patients for genomic alterations in ROS1, ALK, and RET by
performing interphase FISH as previously described [35].
A 5′ deletion of ROS1 was detected by FISH in recovered CTCs from a patient with a known
ROS1 rearrangement in the primary tumor (P 03) (Figure 5A). Similarly, an ALK fusion was noted in
the CTCs, matching the patient’s primary tumor (P 17) (Figure 5B), and a 3′ deletion of RET was found
in recovered CTCs from a patient with a RET rearranged tumor (P 26) (Figure 5C).
The total numbers of CTCs/mL in all patients with respect to their EGFR/ROS1/ALK status are
shown in Figure 5D. Patients with EGFR mutations (n = 15) had an average 559 CTCs/mL (10–5068),
those with ROS1 rearrangements (n = 6) had an average of 220 CTCs/mL (15–551), and those with ALK
fusion (n = 4) had an average of 178 CTCs/mL (70–363). However, the differences in the number of
CTCs according to genotype were not statistically significant.
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Figure 4. Isolation of CTC clusters from NSCLC patient samples (n = 25) by using Labyrinth.
(A) Immunofluorescence staining images of the representative recovered CTC clusters in NCSLC
patients. CTC clusters are stained with DAPI (blue), CD45 (green), PanCK (red), EpCAM (orange),
and Vimentin (pink). (B) The percentage of CTCs in single (light pink) vs. cluster (red) forms. Across all
patients, only one patient did not have CTC clusters. (C) Comparison between the total CTC numbers
in single and cluster forms. Significantly higher numbers of clusters compared to the single CTCs were
observed in the captured CTCs from NSCLC patients (n = 25) (p = 0.001). (D) Cell clusters of 2–8 CTCs
were observed in 96% of patients. (E) Of the recovered CTC clusters, 41% displayed a mesenchymal or
epithelial-to-mesenchymal transition (EMT) phenotype (97 CTC clusters/mL) (p = 0.007). Wilcoxon test
analysis was used for comparing single vs. clusters CTCs and EpCAM+ vs. Vimentin+ CTCs. Analyses
were conducted using GraphPad Prism. (F) Comparison of Kaplan–Meier progression-free survival
(PFS) graph in patient samples (n = 24) with a higher number of clusters than single CTCs (n = 10) (red)
and in patients who had a higher number of single CTCs (n = 14) (black). A higher number of CTC
clusters than the single CTCs was correlated with worse PFS (p = 0.05). Log-rank (Mantel–Cox) tests
were used to analyze the Kaplan–Meier PFS.
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Figure 5. Genomic analysis of NSCLC patient samples using fluorescence in situ hybridization (FISH)
analysis. (A–C) Recovered CTCs from selected patient samples with different mutations (ROS1, ALK,
and RET) were evaluated. (A) A patient with ROS1 rearrangement showed 5′ deletion in some of the
cells. (B) A patient with aberration in ALK showed ALK fusion. (C) A patient with aberration in RET
showed 3′ deletion. Arrows indicate specific aberration in each gene. (D) Box plot of the total number
of CTCs recovered from patients with different mutations (EGFR (n = 15), ROS1 (n = 6), and ALK
(n = 4)). Analyses were conducted using GraphPad Prism.
3. Discussion
The field of study involving circulating tumor cells (CTCs) as well as circulating tumor DNA
(ctDNA) has evolved at a rapid pace that may eventually provide a valuable point of care assessment
that could be used to both predict the effectiveness of specific targeted therapies as well as prognosticate
cancer outcomes respectively. Specifically, ctDNA is an established test for example for EGFR mutant
lung adenocarcinoma to both diagnose and follow patients being treated with targeted therapies. CTCs
on the other hand may be used in the future to reflect both the genotype and the phenotype of the
underlying cancer and may serve as an ex vivo predictor of targeted drug sensitivity, using expanded
CTCs. Therefore, CTCs may serve as a valuable adjunct to blood-based ctDNA that is currently in
advanced stages of development for the detection of specific molecular subtypes of NSCLC. CTC
clusters are rarer than single CTCs [8] and they have a short half-life of less than 2.5 h in circulation [36],
therefore, isolation techniques must be sufficiently sensitive to identify, enumerate, and isolate intact
CTC clusters in a reasonable time with minimal manipulation.
Current methods for isolation of CTCs and CTC clusters mostly rely on biomarker-dependent
antibody-based capture. CTC clusters demonstrate a hybrid of epithelial–mesenchymal character.
Moreover, multicellular clusters have a much smaller area-to-volume ratio thus minimizing
antibody-binding regions [8]. Therefore, current isolation techniques, can underestimate CTC/clusters
populations that may be stem-like or mesenchymal in phenotype, hampering detecting of heterogeneous
populations of cancer cells.
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Hence, biomarker-independent technologies are eventually taking the lead in the field.
By removing the bias of using molecular markers for CTC/clusters isolation, heterogeneous CTC/cluster
subpopulations can be recovered using label-free isolation. Each subpopulation may carry distinct,
important information that could predict patient outcomes.
As demonstrated previously, Labyrinth incorporated both inertial focusing and Dean flow for
size-based separation, enabling the continuous focusing of all cells while separating CTCs from smaller
blood cells at the outlet [25]. In summary, the Labyrinth device employs a combination of long
curvature structure with loops and sharp corners to enhance differential focusing, allowing ease of
separation of CTCs and white blood cells (WBCs) from patient blood samples [25]. The loops have a
small curvature ratio to provide enough channel length to achieve the total focusing of CTCs from
other blood cells. In contrast, the sharp corners have a high curvature ratio to enhance the focusing of
blood cells. The major difference between Labyrinth and all other spiral designs lies in the numerous
corners placed across the flow pattern. It is proposed by Sun et al. that the sharp change in flow
direction can increase the focusing of smaller particles (e.g., WBCs) [37].
We determined that 100% of processed NSCLC patient samples (n = 25) had detectable CTCs,
with an average of 417 CTC/mL with the number of CTCs/mL ≥10 in 100%, ≥50 in 80%, ≥100 in 64%,
≥200 in 32%, ≥400 in 12%, and ≥1000 in 8% of NSCLC patient samples. Furthermore, of the recovered
CTCs, a significantly higher number of EpCAM− compared to EpCAM+ CTCs were detected (p = 0.01).
As such, CTC detection based only on EpCAM (EpCAM+) might have missed a substantial number of
tumor cells [20,38].
High numbers of CTCs have been reported by others previously [39]. It is not unusual to observe
a high number of CTCs in metastatic lung cancer patients [27,40]. Moreover, the numbers of CTCs do
vary with the treatment response or resistance [41–44]. Hence, based on our healthy controls and also
from the downstream genetic analysis confirming that CTCs presenting matched molecular signatures
to the primary tumor, we are confident that the CTCs we observe in patients are clinically relevant.
We have monitored CTC counts on therapy, and we have observed that CTC counts match
patient’s outcomes. For example, ten consecutive samples from patient P 14 were collected during
different treatment regimens. The numbers of CTCs were analyzed during follow-up visits (Figure 6).
This patient enrolled on this study following progression of her cancer after initially receiving four
cycles of adjuvant chemotherapy with cisplatin/gemcitabine. She was noted to have an EGFR mutation
and subsequently underwent therapy with erlotinib, afatinib, osimertinib (various tyrosine kinase
inhibitors due to tolerability of therapy). Following further progression, she received chemotherapy
with carboplatin/pemetrexed as well as radiation to brain metastasis. She was then placed on
chemotherapy with pemetrexed. Higher numbers of CTCs were observed in her 2nd and 3rd visits
compared to 1st visit (reflecting progression of her cancer on therapy). After 183 days (visits 3–4),
her brain MRI showed an interval increase in the size of lesions at the junction of L frontal/parietal
lobes and a new 5 mm lesion in L posterior fossa. She underwent stereotactic radiation to the brain
lesions. However, at 238 days, she continued to show further progression in the brain. Her CTC counts
increased at these visits compared to the previous follow-up visits. After 400 days the brain MRI
showed response to treatment. Mild reduction in the size of known supra and infratentorial metastatic
lesions and reduced degree of associated edema was observed. Her CTC counts were dropped
drastically. After 425 days CT on chest showed subtle growth of several lung nodules consistent
with metastatic disease progression. Her CTC counts increased again, in keeping with this thoracic
progression and the counts continued to increase until she was placed on pemetrexed chemotherapy,
when the CTC counts dropped. In summary, according to the available clinical information, the CTC
numbers tracked the patient’s outcome over the course of treatment.
Cancers 2020, 12, 127 11 of 17
Figure 6. CTC enumeration of one NSCLC patient over the treatment regime. In total, 10 different
follow-up samples from patient P 14 were collected and the CTC numbers were evaluated over different
treatments. According to the available clinical information, the CTC numbers tracked the patient’s
outcome over the course of treatment.
It has been reported that the CTC clusters have a high propensity for survival in circulation and in
the development of metastases [9]. Using the Labyrinth, we were able to not only isolate CTCs in a
single form, but also in clusters (p = 0.001). Patients who had a higher number of CTC clusters than
single CTCs had worse PFS. However, the observation was not significant in this cohort which could be
due to the limited sample size (p = 0.05). We believe that these CTC clusters may provide an important
tool to be used in mice studies (CTC cluster derived xenografts) to understand key biological processes
such as metastases to specific organs. Additionally, these CTC clusters can be used to develop organoid
models that can serve as a platform for ex vivo expansion and drug. The latter application can assist
the clinician in identifying the “best in class” tyrosine kinase inhibitor (TKI) against a specific target.
The discovery and development of small molecule TKIs has revolutionized therapy for specific
molecular subsets of NSCLC patients [45]. However, the majority of patients will develop resistance to
TKIs within a few months/years [45,46]. The resistance is often mediated by a secondary mutation in
the target gene or alternative pathways that supervene and bypass the original signaling pathway [47].
Presently, the gold standard to ascertain mechanism of resistance is to perform a re-biopsy [48,49].
Real-time PCR (qPCR) [50], digital PCR (dPCR) [51], and NGS (Next-Generation Sequencing)
technologies have been incorporated in detecting ctDNA, which is becoming a reliable alternative
to tissue biopsies. Once the resistance mechanism is identified, there are newer therapies available
to target the resistance mechanism. However, there is no definitive method to identify which one
of the various drugs that target the “resistance causing mutation” might be the most effective for an
individual patient [47]. There is, therefore, an unmet need, not only to identify resistance early and
without a tissue biopsy, but also for drug sensitivity assays that predict response ex vivo. CTC/CTC
cluster isolation as a non-invasive method could help to identify primary and secondary resistance
mutations and allow for ex vivo drug testing to direct therapy specific to the patient.
We hereby present a novel platform, the Labyrinth that is not only highly sensitive for CTC
and CTC cluster isolation, but also highly specific in detecting specific oncogenic driver mutations,
reflective of the underlying cancer. Furthermore, CTC numbers measured CTCs over the course of
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therapy reflected patient clinical outcomes. We will focus our next set of studies in expanding these
CTCs/clusters to develop ex vivo drug testing platforms.
4. Materials and Methods
4.1. Microfabrication
The fabrication of Labyrinth devices includes the design of film mask, the fabrication of SU-8
mold in clean room, and the fabrication of poly-dimethyl siloxane (PDMS) (Ellsworth Adhesives,
Germantown, WI, USA) device in laboratory. The film mask was designed in laboratory using L-Edit
software. The design was converted to a photomask (FineLine Imaging, Colorado Springs, CO, USA)
and used to prepare a mold by traditional photolithography. In short, a negative photoresist SU-8 100
was utilized to form the mold for the PDMS device by applying soft lithography. Using a spin-coater,
the negative photoresist layer, SU-8 100, was deposited onto silicon wafer with 2450 rpm rotating for
1 min. The wafer was then soft-baked for 10 min at 65 ◦C and 70 min at 95 ◦C. The mask was aligned to
the wafer and is exposed to UV light for 20 s. Post-exposure-baking was applied for 3 min at 65 ◦C and
10 min at 95 ◦C. Then, the wafer was developed by soaking in developer for 6 min and in isopropyl
alcohol (IPA) for 1 min to remove the inactivated photoresist. It was hard baked for 3 min at 150 ◦C.
The height of the mold built on silicon wafer was ideally 100 µm, and the width of the channel was
500 µm.
To prepare the PDMS device from fabricated mold, 30 mL Sylgard polymer base and 3 mL curing
agent were mixed well and poured onto silicon mold. The mixture was left in desiccator for 2 h to
remove trapped air within the mixture. It was then heated at 65 ◦C overnight to harden the polymer.
The polymer was cut into the desired shape, e.g., rectangular for Labyrinth, and punched with a needle
for tubing later. The PDMS device was then bonded to standard-sized glass slides via plasma surface
activation of oxygen. The bonded device was tubed with 0.66 mm diameter tubes.
4.2. Labyrinth Device
The design of the Labyrinth device was inspired by the Labyrinth in Greek mythology [25].
The device consists of 11 long loops and 56 sharp corners, with a total channel length of 637 mm, at a
width of 500 µm and height of 100 µm. The device has one inlet and 4 outlet channels. The width of
outlet #1 is 135 µm, outlet #2 is 180 µm, outlet #3 is 135 µm, and outlet #4 is 400 µm. The outlets were
designed such that outlet #1 collects WBCs, outlet #2 collects CTCs, and outlets #3 and #4 collect other
blood components.
4.3. Cell Preparation
Human lung cancer cell lines H1650, A549, and H1975 (ATCC) were cultured in RPMI 1640
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad,
CA, USA) and maintained in an incubator at 37 ◦C in 5% CO2 and 95% relative humidity. Upon reaching
>75%–80% confluence, the cells were harvested with 0.05% trypsin-EDTA (Ethylenediaminetetraacetic
acid) (Invitrogen, Carlsbad, CA, USA). Prior to characterization experiments, cells were labeled with
CellTracker™Green CMFDA Dye (Invitrogen, Carlsbad, CA, USA). The density of cell suspensions was
counted using a hemocytometer and spiked into phosphate-buffered saline (PBS) or healthy control
(HC) blood for analysis of CTCs recovery from Labyrinth.
4.4. Characterization Experiments for Labyrinth (Cell Lines)
The Labyrinth was primed with 1% Pluronic acid solution (diluted in 1× PBS) at a flow rate
of 100 µL/min for 10 min and then incubated for 10 min to prevent cell adhesion to channel walls.
To demonstrate cell specificity using the Labyrinth, the same number of pre-labeled cancer cells (from
cell lines) and DAPI-labeled WBCs (each 1000 cells/mL) were mixed and spiked into PBS and flowed
through the device at different flow rates (2300, 2400, 2500 µL/min). After allowing for stabilizing of
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flow streams (1.5 min) within the Labyrinth, products from outlet #2 were collected for cell counting
to calculate the recovery and percent of depleted WBCs. Images were taken using a Nikon Eclipse
Ti fluorescence microscope under FITC and DAPI filters to categorize and document cancer cells in
isolation from other blood components.
4.5. Experimental Protocol for Labyrinth (Patient Samples)
The experimental protocol was approved by the Ethics committee (Institutional Review Board and
Scientific Review Committee) of the University of Michigan. All patients and healthy blood donors
gave their informed consent to participate in the study (HUM00119934). The patients had to have a
diagnosis of driver mutant lung adenocarcinoma for whom a targeted therapy option was available.
Briefly, 5 mL of blood was collected in EDTA tubes and processed through the Labyrinth within 2 h
of collection. RBCs in the blood samples were removed using density separation with dextran solution
(6% dextran solution, M.W. 250,000) prior to processing in the Labyrinth. However, there was no
centrifugation step prior to sample processing. The blood sample mixed with dextran solution was kept
at room temperature for 1 h to allow the RBCs to settle, aided by density difference. The supernatant,
which included all whole blood components except RBCs, was carefully removed and diluted with
PBS (1:3). The diluted dextran supernatant was then processed through the Labyrinth at a flow rate of
2500 µL/min. The product from outlet #2 was collected after stabilization.
4.6. Immunofluorescence (IF) Staining
The product from outlet #2 was processed using a Thermo Scientific TM Cytospin Cytocentrifuge
(Kalamazoo, MI, USA). A poly-lysine coated slide was placed into the cytospin funnel and 250 µL
of sample was added to each cytospin funnel and cytocentrifuged at a speed of 800 rpm for 10 min.
Samples were fixed on the cytoslides using 4% paraformaldehyde (PFA) and cytocentrifuged at the
same conditions as described above. Slide samples were permeabilized by applying 0.2% Triton X-100
solution for 3 min. Slides were then washed with PBS (X 3) for 5 min and blocked using 10% donkey
serum for 30 min at room temperature.
The panel of antibodies (mouse anti-human CD45 (IgG2a, Biorad, Hercules, CA, USA), mouse
anti-human PanCK (IgG1 Biorad, Hercules, CA, USA), anti-human EpCAM, biotinylated (goat IgG,
R&D systems, Minneapolis, MN, USA), and rabbit anti-human Vimentin (Abcam, Cambridge, MA,
USA) were optimized using lung cancer cell lines including H1975 and A549. The slides were
then incubated with a cocktail of primary antibodies (anti-CD45, anti-PanCK, anti-EpCAM, and
anti-Vimentin) overnight at 4 ◦C, followed by PBS wash (X 3) for 5 min the following day. Slides were
incubated in the dark with secondary antibodies (Alexa Fluor 488, 546, 750, and 647) for 1.5 h at room
temperature. Finally, slides were washed with PBS (X 3) for 5 min and mounted using Prolong Gold
Antifade Mountant with DAPI. The immunofluorescently stained slides were imaged using a Nikon TI
fluorescent microscope at 20X magnification for enumeration.
4.7. Fluorescence In Situ Hybridization (FISH) Analysis
Bacterial artificial chromosomes (BACs) were obtained from the BACPAC Resource Center
(Oakland, CA, USA) for the preparation of probes. For the detection of gene rearrangements, deletion
or amplification, the following probes were used: for ROS1, RP11-1110L9 (5′ to ROS1) and RP11-605K7
(3′ to ROS1), for RET, RP11-124O11 (5′ to RET) and RP11-718J13 (3′ to RET), for EGFR, RP11-23F4 (5′
to EGFR) and RP11-56P1 (3′ to EGFR), and for ALK, RP11-993C21 (5′ to ALK) and RP11-984I21 (3′ to
ALK). The integrity and accurate localization of all probes were verified by hybridization to metaphase
spreads prepared from normal peripheral lymphocytes. Slides were examined using a Zeiss Axioplan
2 microscope equipped with image processing software ISIS (Metasystems). FISH signals were scored
manually under 100× oil immersion in morphologically intact and non-overlapping nuclei and greater
than 100 cells from each slide were recorded.
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4.8. Statistical Analysis
All results are presented as the mean ± standard deviation. The Mann–Whitney test (two-tailed)
was used to compare the differences between total numbers of CTCs in patient samples (n = 25) and
healthy controls (n = 3). Wilcoxon test were used to compare EpCAM+ and EpCAM− CTCs, Vimentin+
and Vimentin− CTCs, as well as single CTC vs. CTC clusters. Mann–Whitney unpaired t-test analysis
was used for comparing patient cohort (n = 25) vs. healthy controls (n = 3). Log-rank (Mantel–Cox)
tests were used to analyze the Kaplan–Meier progression-free survival (PFS) graph of CTC clusters vs.
single CTCs across patient samples (n = 24). Statistical significance was defined as a two-sided p < 0.05.
Analyses were conducted using GraphPad Prism (San Diego, CA, USA).
5. Conclusions
The present study was devised to evaluate the detection of heterogeneous CTC/cluster populations
isolated from metastatic NSCLC patient blood samples using a high-throughput, label-free, microfluidic
Labyrinth device. CTCs were isolated from these patients whose lung cancers exhibited specific driver
mutations/rearrangements.
Our device not only resulted in a high yield of CTCs but also resulted in capture of heterogeneous
CTC subpopulations. Of recovered CTCs, on average, only 31% of CTCs expressed some level
of EpCAM, emphasizing the need for label-free approaches for studying lung CTCs. In addition,
an average of 45% of CTCs expressed Vimentin. Among 23 analyzed patient samples, 22 samples
had Vimentin+ CTCs, indicating the presence of Vimentin+ EMT-like cells in circulation in NSCLC.
We monitored CTC counts in patients over the course of their therapy and found that the counts
mirrored patient clinical outcomes.
In addition to single CTCs, we have observed CTC clusters (≥2 CTCs) in 96% of NSCLC patients.
Patients who had more CTC clusters had worse PFS. Among the total number of clusters (2754
clusters per mL) recovered from all 23 patient samples, 75% of CTC clusters were negative for EpCAM
expression, whereas 41% of CTC clusters expressed the EMT marker, Vimentin, suggestive of an
EMT phenotype in CTC clusters. These findings indicate the advantage of the label-free approach for
isolating CTC subpopulations in both single and cluster forms.
We have been able to detect tumor-related mutations in CTCs of patients with driver mutant
lung adenocarcinoma. We have shown that recovered CTCs from selected patients with ROS1, ALK,
and RET rearrangements carried genomic aberrations matching the primary tumor.
Although in vivo applications of label-free technologies are still very limited, the capability of
collecting recovered CTCs/clusters from the device using a continuous processing technique while in a
suspension state opens the opportunities not only for CTC expansion off chip, but also for ex vivo
drug testing to direct patient-specific therapies.
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